yaz, a combination oral contraceptive containing drospirenone and ethinyl estradiol, has been approved by the FDA for the treatment of premenstrual dysphoric disorder (PMDD) due to its ability to regulate menstrual cycles and reduce symptoms associated with hormonal fluctuations. Drospirenone, a spironolactone derivative, exhibits anti-androgenic and anti-mineralocorticoid properties that can help alleviate physical and emotional symptoms of PMDD such as bloating, breast tenderness, mood swings, and irritability. Additionally, Yaz can help stabilize estrogen and progesterone levels, leading to a more balanced hormonal environment and potentially reducing the severity of PMDD symptoms. It is important for individuals considering using Yaz for PMDD to consult with a healthcare provider to determine if it is the right treatment option for their specific needs and medical history.

Get more information :-  https://www.actizapharmaceutical.com/product/yaz-tablet/